Larimar Therapeutics Investor Relations Material

Latest events

Study Update

Larimar Therapeutics

Study Update

16 Dec, 2024

Corporate Presentation

30 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Larimar Therapeutics Inc

Access all reports
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. The company's primary focus is on its lead compound, CTI-1601, which is currently being developed as a potential treatment for Friedreich's ataxia, a genetic disorder that affects the nervous system and movement. Larimar leverages its proprietary intracellular delivery platform to design fusion proteins aimed at addressing other rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania, and its shares are listed on the Nasdaq.